אימודיום תמיסה ישראל - עברית - Ministry of Health

אימודיום תמיסה

j-c health care ltd - loperamide hydrochloride 0.2 mg/ml - solution - control and symptomatic relief of acute diarrhea.

דפו-מדרול עם לידוקאין ישראל - עברית - Ministry of Health

דפו-מדרול עם לידוקאין

pfizer pfe pharmaceuticals israel ltd - lidocaine as hydrochloride; methylprednisolone acetate - תרחיף להזרקה - lidocaine as hydrochloride 10 mg/ml; methylprednisolone acetate 40 mg/ml - methylprednisolone, combinations - lidocaine - depo-medrol with lidocaine is indicated as adjunctive therapy for short-term administration (to tide the patient over an acute episode or exacerbation) in: - synovitis of osteoarthritis - rheumatoid arthritis - acute and subacute bursitis - acute gouty arthritis - epicondylitis - acute nonspecific tenosynovitis - post-traumatic osteoarthritis.

וימפט 50 מג ישראל - עברית - Ministry of Health

וימפט 50 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 50 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 100 מג ישראל - עברית - Ministry of Health

וימפט 100 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 100 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 150 מג ישראל - עברית - Ministry of Health

וימפט 150 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 150 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 200 מג ישראל - עברית - Ministry of Health

וימפט 200 מג

neopharm ltd, israel - lacosamide - טבליות מצופות פילם - lacosamide 200 mg - lacosamide - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.

וימפט 10 מ"ג/מ"ל ישראל - עברית - Ministry of Health

וימפט 10 מ"ג/מ"ל

cts ltd - lacosamide 10 mg / 1 ml - solution for infusion - lacosamide - vimpat is indicated as adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalization in patients with epilepsy aged 16 years and older.vimpat solution for infusion is an alternative for patients when oral administration is temporary not feasible.

הלדול 5 מג ישראל - עברית - Ministry of Health

הלדול 5 מג

j-c health care ltd - haloperidol - טבליה - haloperidol 5 mg - haloperidol - haloperidol - management of manifestations of psychotic disorders. control of tics and vocal utterances of tourette's disorder.

הלדול 2 מגמל טיפות ישראל - עברית - Ministry of Health

הלדול 2 מגמל טיפות

j-c health care ltd - haloperidol - תמיסה (פומי) - haloperidol 2 mg/ml - haloperidol - haloperidol - antipsychotic, psychomotor sedative. additionally, in pediatrics, for short-term treatment of tics and vomiting (gilles de la tourettes syndrome).

זיפאדהרה 210 מ"ג ישראל - עברית - Ministry of Health

זיפאדהרה 210 מ"ג

eli lilly israel ltd - olanzapine 210 mg - powder for suspension for injection - olanzapine - zypadhera is indicated for the treatment of schizophrenia.the use of zypadhera is limited to patients who have been diagnosed as non-compliant regarding taking prescribed medicines and as a consequence are prone to outbursts of psychotic episodes .zypadhera is not to be used in patients whose condition is adequately controlled with oral zyprexa .zypadhera is available only through a restricted program which will be conducted according to zypadhera eu risk management plan.for a patient to receive treatment, the prescribers , injection administrators, pharmacists and patients must all be trained on the appropriate elements of the zypadhera risk management plan. the zypadhera risk management plan has been developed to enable the safe use of zypadhera in patients, including the management of those patients who develop post-injection delirium and sedation syndrome. in addition to mandating label language around this risk, this plan includes education and training activities to the following target audience as appr